Home > News > Latest > Penumbra and Veterans Health Administration to Expand Access to Rehabilitative Care using Virtual Reality

Digital Healthcare, Medical Devices

Penumbra and Veterans Health Administration to Expand Access to Rehabilitative Care using Virtual Reality

Penumbra, Inc. a global healthcare company focused on innovative therapies, announced that it will collaborate with the Veterans Health Administration (VHA) Office of Healthcare Innovation and Learning (OHIL) to test, co-develop and implement rehabilitative health care solutions through virtual reality (VR).

"VHA is one of the most impactful and forward-thinking innovators in healthcare, constantly promoting discovery and adoption of the latest technologies to advance care delivery and service," said Gita Barry, president of Penumbra's Immersive Healthcare business. "It is a great honor to work with the VHA on such an important initiative to not only maximize the key benefits of rehabilitation therapy with virtual reality, but to also broadly implement these tools so veterans, whether at a VA facility or in a remote location, will have access to these offerings."

Building on Penumbra's REAL y-Series technology, the collaboration will focus on developing targeted therapy tools that address the most critical rehabilitation needs of veterans, increasing access to care by scaling VR solutions to remote areas and gaining a deep understanding of their needs to help inform future health care offerings. REAL y-Series is the only hands-free, non-tethered, multi-disciplinary VR rehabilitation platform to address high acuity to high functioning patients.

These solutions will largely be used for veteran neurorehabilitation and chronic condition management. Additionally, VHA OHIL will be able to further adopt and scale new technologies for remote therapeutic rehabilitation, remote therapeutic monitoring, and remote patient management as this solution will support asynchronous patient-provider interactions.

The REAL y-Series is currently being used in clinics and hospitals across the country to address physical rehabilitation, core and balance, cognition, functional uses, and activities of daily living.

About the REAL Immersive System Platform

Penumbra's REAL Immersive System is a platform of products that leverages virtual reality to deliver engaging, immersive healthcare designed to promote better health, including furthering functional skills, cognition and stress management. Built on advanced technology with a growing library of VR-based activities and experiences, the REAL Immersive System platform is comprised of two product solutions: REAL y-Series for clinical rehabilitation and REAL i-Series for wellness.

About Penumbra

Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries.

Spotlight

Other News

Health Technology

CareView Launches Software 5.10 for Improved Virtual Care Solutions

CareView Communications | September 13, 2023

CareView Communications, Inc., a prominent provider of integrated virtual care solutions for the healthcare sector, has announced the introduction of its most recent milestone in patient care technology through the unveiling of Software Version 5.10. This release incorporates many cutting-edge features and improvements meticulously crafted to empower healthcare professionals and enhance patient results. Software Release 5.10 introduces a range of significant enhancements, beginning with the seamless integration of CareView with Get Well, a leading patient engagement platform. This integration facilitates bidirectional video communication, ultimately elevating patient engagement, education, and overall satisfaction. Additionally, a new Universal Dashboard has been introduced. This internal tool plays a crucial role in optimizing solutions. It leverages hospital utilization data along with machine learning algorithms to provide predictive analytics and enables in-depth analyses, significantly enhancing the overall offerings. Derek del Carpio, CareView's VP of Product Development, stated, At CareView, we continuously strive to provide innovative solutions that redefine patient care. Software Release 5.10 is a testament to our commitment to advancing virtual care technology and enhancing the well-being of patients. [Source: Business Wire] Further, substantial improvements have been applied to the Virtual Sitting feature, empowering CareView Controllers to manipulate associated views through EquipmentView and introducing Night Mode in SitterView to reduce eye strain, thus enhancing both patient monitoring flexibility and safety. Virtual Nursing has also undergone notable refinements, enabling the virtual Registered Nurse to mute participants during TeleCareView encounters, facilitating participants' easy transition between viewing fellow participants and shared screens, and granting healthcare providers the capability to blur backgrounds in TeleCareView, thereby fostering a more professional and focused virtual interaction environment. CareView maintains a steadfast commitment to fostering collaboration with healthcare providers to elevate patient safety, optimize clinical processes, and enhance overall patient care quality. Introducing this latest software release further underscores CareView's unwavering dedication to providing hospital teams with innovative virtual care solutions to meet their evolving needs. About CareView Communications CareView, leveraging predictive technology and purpose-built hardware, has forged partnerships with more than 200 hospitals to tackle pressing staffing issues and elevate patient safety through its platform. The company collaborates closely with its hospital partners to deliver tailored virtual care strategies that improve patient outcomes and foster a sustainable healthcare ecosystem.

Healthcare Analytics

FDA Grants De Novo for Xenex's LightStrike+ UV Robot in Healthcare

Xenex | September 11, 2023

United States Food and Drug Administration (USFDA) has issued a De Novo authorization to Xenex Disinfection Services, Inc. (Xenex) for its LightStrikeTM+ device, an advanced high-intensity, broad-spectrum ultraviolet (UV) light robot. The LightStrike+ devices are designed for microbial reduction on non-critical medical device surfaces in healthcare environments, following manual cleaning and disinfection practices. They are authorized for use in various healthcare settings, including unoccupied operating rooms and hospital rooms. These devices have an impressive track record, with over 1,200 healthcare facilities worldwide employing LightStrike robots for over 37 million cycles. The new LightStrike+ device, capable of microbial reduction in as little as 2 minutes, represents the culmination of over a decade of knowledge accumulation from healthcare facilities' best practices, supported by 45 peer-reviewed studies demonstrating its safety and effectiveness, a portfolio of 193 patents, and unparalleled technical and epidemiological expertise. Dr. Mark 'Tuck' Stibich, Xenex's Founder and Chief Scientific Officer, emphasized the long-standing collaboration with healthcare partners spanning more than a decade to enhance patient safety and public health. As an infectious diseases epidemiologist, Dr. Stibich expressed concern about antibiotic resistance within hospital environments and the potential for FDA authorization to facilitate the broader adoption of the LightStrike+ tool in combating pathogens. Perilous pathogens persist on surfaces within healthcare facilities, notwithstanding diligent manual cleaning endeavors. The LightStrike+ robot employs a xenon lamp to generate high-intensity pulsed UV light, which effectively diminishes the presence of these pathogens on surfaces and plays a pivotal role in interrupting the transmission chain from one patient or healthcare worker to another. Xenex's FDA authorization is substantiated by comprehensive testing conducted on more than 10,000 samples of vegetative bacteria and Clostridiodes difficile (C. diff) spores. This authorization establishes a novel medical device product classification, with the LightStrike+ robot being its inaugural and sole product. It is a landmark in the FDA's regulatory framework for UV robots designed to diminish pathogens on non-porous, frequently touched surfaces within healthcare settings. Furthermore, Xenex's Chief Executive Officer, Morris Miller, acknowledged the challenges hospitals face when evaluating UV technologies, citing the prevalence of unverified and exaggerated claims by some manufacturers. He underscored the significance of FDA authorization in instilling confidence among hospital decision-makers, assuring them of the accuracy and validation of Xenex's claims regarding the LightStrike+ device. Numerous world-renowned hospitals, such as HonorHealth, Mayo Clinic, MD Anderson Cancer Center, Ochsner Health System, Stanford Health Care, and Texas Health Resources, have integrated LightStrike robots into their comprehensive disinfection strategies. About Xenex Xenex is a global leader in pioneering strategies and solutions grounded in UV technology. Its fundamental mission revolves around enabling its partners to safeguard lives and reduce human suffering by eliminating the dangerous microorganisms that cause infections. The company benefits from substantial support from renowned investors, including EW Healthcare Partners, Piper Sandler, Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures, and RK Ventures.

Health Technology

Ovation Healthcare Expands Portfolio with Launch of Tempo Technology Services

PR Newswire | October 25, 2023

Ovation Healthcare, a premier provider of shared services to independent hospitals and health systems nationwide, today announced the launch of Tempo Technology Services (Tempo). Tempo will complement the Ovation Healthcare portfolio with managed and professional IT services in addition to procurement of hardware, logistics services, and other devices to simplify decision making and optimize clinical and operational performance. said Ovation Healthcare CEO Dr. Dwayne Gunter. We're thrilled to announce the launch of Tempo, which is designed to revolutionize the way hospitals manage their clinical operations. Tempo creates value for our client hospitals and health systems by delivering innovative technology solutions that promote efficiency, transparency, and most importantly, better health outcomes. [Source:PR Newswire] Through a portfolio of tech-enabled shared services, Ovation Healthcare helps independent hospitals outperform their peers in financial, operational, and quality metrics through leverage and economies of scale. The addition of Tempo's services will further support hospitals and health systems in optimizing technology investments, maintaining regulatory compliance, and adopting new capabilities. About Ovation Healthcare Headquartered in Brentwood, Tenn., Ovation Healthcare is partnered with 375+ clients in 47 states from critical access hospitals to large health systems. For 45 years, Ovation Healthcare has supported nonprofit, independent healthcare through a portfolio of shared services – Octave Leadership Advisory Services, Elevate Supply and Expense Management Solutions, Amplify Revenue Cycle Management, Cadence Clinical Services, and Tempo Technology Services – designed to provide scale and efficiency to hospital business operations.

Healthcare Analytics

AirLife Completes Acquisition of Avanos Medical’s Respiratory Health Business

Business Wire | October 04, 2023

AirLife, a leading North American manufacturer and distributor of consumable medical devices for anesthesia and respiratory care formerly known as SunMed, today announced the completion of its acquisition of Avanos Medical, Inc.’s (NYSE: AVNS) (“Avanos”) respiratory health business, including the BALLARD*, MICROCUFF* and endOclear® product lines. The acquisition adds three complementary brands, the R&D expertise behind them and two manufacturing facilities into AirLife’s growing platform. The transaction advances AirLife’s strategy to enhance its leading portfolio of the most trusted products in anesthesia and respiratory care and serve even more customers as a one-stop source for the highest-quality consumable breathing solutions that support the best patient outcomes. “We’re thrilled to complete this exciting milestone in AirLife’s evolution as we strengthen our leadership as a premier, completely dedicated consumable breathing products company,” said Hank Struik, AirLife CEO. We are especially pleased to welcome the exceptional team that has driven the success of these market leading brands to our company. As some of the most trusted closed suction and endotracheal consumables used to treat patients in critical care, this addition to AirLife unlocks new opportunities to accelerate our growth, serve more healthcare practitioners and drive innovation across our comprehensive portfolio of leading brands. [Source – Business Wire] Goodwin Procter LLP is acting as legal counsel to AirLife. About AirLife AirLife, formerly known as SunMed and headquartered in Grand Rapids, Michigan with manufacturing and distribution sites in the United States, Mexico, China and Europe, is a leading medical device manufacturer, offering one of the most comprehensive portfolios of consumable anesthesia and respiratory care products. AirLife’s product portfolio spans the continuum of care from first responders to hospitals and home care, with safety, patient comfort and clinical performance in mind. AirLife’s comprehensive portfolio of trusted anesthesia products and respiratory care include premier brands such as Salter Labs®, Ethox Medical™, Ventlab™, Westmed™, AirLife™ and Vital Signs™. Currently, AirLife has over 1 million square feet of manufacturing space, providing comprehensive expertise in all plastics materials and conversion—supported by a world-class Quality Management System. Frazier Healthcare Partners, a leading healthcare investment firm, acquired a majority ownership stake in AirLife in 2021.